ROCHESTER, N.Y., Jan. 11, 2016 (GLOBE NEWSWIRE) -- Transcat, Inc. (NASDAQ:TRNS) (“Transcat” or the “Company”), a leading provider of accredited calibration and compliance services and distributor of professional grade handheld test, measurement and control instrumentation, announced today that it will release its third quarter fiscal year 2016 results before the opening of financial markets on Monday, January 25, 2016.
The Company will host a conference call and webcast to review the financial and operating results for the period and discuss its corporate strategy and outlook. A question-and-answer session will follow.
Third Quarter Fiscal Year 2016 Conference Call
Monday, January 25, 2016
11:00 a.m. Eastern Time
Phone: (201) 689-8471
Internet Webcast: www.transcat.com/investor-relations
A telephonic replay will be available from 2:00 p.m. ET on the day of the teleconference until Monday, February 1, 2016. To listen to the archived call, dial (858) 384-5517 and enter conference ID number 13627606, or access the webcast replay via the Company website at www.transcat.com/investor-relations, where a transcript will be posted once available.
ABOUT TRANSCAT
Transcat, Inc. is a leading provider of accredited calibration and compliance services, including analytical instrument qualifications, equipment and process validation. The Company is focused on providing best-in-class calibration analytics to highly regulated industries, including life science, aerospace, pharmaceuticals, medical device manufacturing and biotechnology. Transcat performs over 250,000 specialized technical services annually through a variety of delivery options, including permanent and periodic on-site services, mobile calibration services and in-house services (often accompanied by pick-up and delivery). The in-house services are offered through 20 Calibration Service Centers strategically located across the United States, Puerto Rico and Canada. The breadth and depth of measurement parameters addressed by Transcat’s ISO/IEC 17025 scopes of accreditation are believed to be the best in the industry. Transcat also answers the call with cGMP and GLP compliant services.
In addition, Transcat operates as a leading distributor of professional grade handheld test, measurement and control instrumentation, marketing more than 100,000 premier and proprietary brand instruments to approximately 22,000 customers.
Transcat’s growth strategy is to leverage its service capabilities, strong brand and leading distribution platform to drive organic sales growth and to expand its addressable calibration market through acquisitions and capability investments to further realize the inherent leverage of its business model.
More information about Transcat can be found on its website at: Transcat.com.
For more information contact: John J. Zimmer, Chief Financial Officer Phone: (585) 352-7777 Email: [email protected] Deborah K. Pawlowski, Investor Relations Phone: (716) 843-3908 Email: [email protected]


Luxury Car Sales in the Middle East Take a Hit Amid Iran War
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
UPS and Teamsters Reach Agreement to Limit Driver Severance Program
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions
Britain Courts Anthropic Amid US Defense Department Dispute
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 



